7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Lung Neoplasms D008175 171 associated lipids
Wounds and Injuries D014947 20 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Inflammation D007249 119 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Nephropathies D003928 39 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Speer G et al. Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients. 2008 Nephrol. Dial. Transplant. pmid:18450827
Shroff RC et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. 2008 Nephrol. Dial. Transplant. pmid:18463323
Ford ML et al. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. 2012 Nephrol. Dial. Transplant. pmid:21750158
Schinke T and Karsenty G Vascular calcification--a passive process in need of inhibitors. 2000 Nephrol. Dial. Transplant. pmid:10978374
Cianciolo G et al. Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients. 2011 Nephrol. Dial. Transplant. pmid:20659908
Sasaki N et al. Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. 2001 Nephrol. Dial. Transplant. pmid:11239019
Graciolli FG et al. Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. 2009 Nephrol. Dial. Transplant. pmid:19075196
Avbersek-Luznik I et al. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? 2005 Nephrol. Dial. Transplant. pmid:15665031
Sigrist MK et al. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. 2009 Nephrol. Dial. Transplant. pmid:19491380
Messa P et al. Calcimimetic increases osteoprotegerin and decreases fetuin-A levels in dialysis patients. 2007 Nephrol. Dial. Transplant. pmid:17526536
Morena M et al. A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. 2009 Nephrol. Dial. Transplant. pmid:19574342
Svensson M et al. Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study. 2012 Nephrol. Dial. Transplant. pmid:22172725
Kazama JJ et al. Circulating osteoprotegerin is not removed through haemodialysis membrane. 2002 Nephrol. Dial. Transplant. pmid:12271009
Nitta K et al. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. 2004 Nephrol. Dial. Transplant. pmid:15128884
Coen G et al. Serum osteoprotegerin and renal osteodystrophy. 2002 Nephrol. Dial. Transplant. pmid:11812872
Jiang JQ et al. Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder. 2011 Nephrology (Carlton) pmid:21649792
Ozkaya O et al. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis. 2007 Nephron Clin Pract pmid:17259742
Kim HR et al. The ratio of osteoprotegerin to fetuin-a is independently associated with vascular stiffness in hemodialysis patients. 2013 Nephron Clin Pract pmid:23921088
Kurnatowska I et al. Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients. 2011 Nephron Clin Pract pmid:20861651
Kao SY et al. Loss of osteoprotegerin expression in the inner ear causes degeneration of the cochlear nerve and sensorineural hearing loss. 2013 Neurobiol. Dis. pmid:23607938
Bergestuen DS et al. Activin A in carcinoid heart disease: a possible role in diagnosis and pathogenesis. 2010 Neuroendocrinology pmid:20720391
Kokkotou E et al. Serum correlates of the placebo effect in irritable bowel syndrome. 2010 Neurogastroenterol. Motil. pmid:20028464
Erdogan B et al. Intima-media thickness of the carotid arteries is related to serum osteoprotegerin levels in healthy postmenopausal women. 2004 Neurol. Res. pmid:15327755
Sen O et al. The relation between serum levels of osteoprotegerin and postoperative epidural fibrosis in patients who underwent surgery for lumbar disc herniation. 2005 Neurol. Res. pmid:15949247
Jefferson AL et al. Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. 2007 Neurology pmid:17389308
Ishizuka K et al. Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. 2005 Neurosci. Lett. pmid:15814197
Shiota J et al. [Relationship between coronary and abdominal calcification score, serum osteoprotegerin (OPG), and serum tartrate-resistant acid phosphatase (TRACP) -5b in pre-dialysis CKD patients]. 2010 Nihon Jinzo Gakkai Shi pmid:21254698
Kaneko K and Kawai S [Mechanisms and therapeutics of glucocorticoid-induced osteoporosis]. 2011 Nihon Rinsho Meneki Gakkai Kaishi pmid:21720102
Tanaka Y et al. [Mesenchymal stem cells for the treatment and repair of inflammatory arthritis]. 2015 Nihon Rinsho Meneki Gakkai Kaishi pmid:26016635
Kozaki K [Current concepts of vascular calcification]. 2005 Nihon Ronen Igakkai Zasshi pmid:16408509
Suzuki Y [Clinical significance of biomarkers in diagnosis of metabolic bone diseases]. 2007 Nippon Naika Gakkai Zasshi pmid:18044149
Kotake S et al. [Molecular mechanism of bone metabolism]. 2000 Nippon Naika Gakkai Zasshi pmid:11215116
Tanaka Y and Okada Y [Progress in therapy and diagnosis: Hypercalcemia due to parathyroid hormone-related protein producing neoplasms]. 2007 Nippon Naika Gakkai Zasshi pmid:17506302
Suda T and Miyaura C [Recent advance in basic research for osteoporosis]. 2004 Nippon Rinsho pmid:15035090
Matsumoto T [Recent advances in the regulation of bone remodeling]. 2004 Nippon Rinsho pmid:15035093
Okumura S et al. [Regulatory mechanism of osteoclast differentiation and function]. 2004 Nippon Rinsho pmid:15035103
Tsuda E [Osteoclastogenesis inhibitory factor (OCIF)/OPG (a novel therapeutic candidate for the treatment of metabolic bone diseases)]. 2002 Nippon Rinsho pmid:11979969
Udagawa N et al. [Possible role of RANKL in bone resorption]. 2004 Nippon Rinsho pmid:15035104
Koshihara Y [Recent progress of bone cell culture system (review)]. 2002 Nippon Rinsho pmid:11979973
Inoue D [OPG(osteoprotegerin)/OCIF(osteoclastogenesis inhibitory factor)]. 2004 Nippon Rinsho pmid:15035105
Suzuki Y [Stimulator of bone resorption interleukin-1, interleukin-6 and gp-130 cytokine family]. 2004 Nippon Rinsho pmid:15035106
Tsuda E and Higashio K [Osteoclastogenesis inhibitory factor (OCIF)/OPG]. 1998 Nippon Rinsho pmid:9648461
Sato K [Osteoclast-activating factors (OAF)]. 2004 Nippon Rinsho pmid:15658306
Chaki O [Osteoporosis]. 2006 Nippon Rinsho pmid:16689336
Takahashi N et al. [Osteoprotegerin (OPG)]. 2010 Nippon Rinsho pmid:20960766
Yasuda H [OPG, anti-rANKL antibody]. 2005 Nippon Rinsho pmid:16164225
Takahashi N et al. [Osteoprotegerin (OPG)]. 2005 Nippon Rinsho pmid:16149650
Takayanagi H [Cross-talk between immune and skeletal systems]. 2002 Nippon Rinsho pmid:12510352
Nakamura M et al. [Osteoclastogenesis and bone resorption]. 2009 Nippon Rinsho pmid:19432105
Masuda H and Tanaka S [Drugs under development for osteoporosis ]. 2009 Nippon Rinsho pmid:19432120

Table of Content